Proactive Investors - Run By Investors For Investors

Avacta rises as it secures licensing deal with New England Biolabs for Affimer technology

The biotechnology firm said it had been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis)
Enzyme
The Affimers can be used to modulate the performance of several of NEB's enzymes in response to temperature

Shares in Avacta Group Plc (LON:AVCT) were on the up in late-morning trading Wednesday after it signed a licensing deal with New England Biolabs (NEB), an enzyme discovery and production company, to commercialise its Affimer technology for use in life science research and diagnostic assays.

The biotechnology firm said it had been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis).

WATCH: Avacta Group CEO Alastair Smith confident of licensing deals this year

Avacta has also identified Affimers that inhibit several of NEB’s proprietary enzymes to provide modulation of their activity in response to temperature.

Unlike alternative enzyme inhibitors, Affimers can be fine-tuned to switch at the right temperature without having a negative effect on the overall assay performance.

NEB was in the final stages of product testing and had agreed with Avacta the terms under which the combined product would be commercialised.

While the financial details of the agreement were not disclosed, Avacata said it would receive a royalty on product sales, which could begin as soon as 2019.

The company added that it expected to continue the collaboration with NEB to generate Affimer tools and inhibitors for other enzymes, enabling further product developments.

Alastair Smith, chief executive of Avacta, said the agreement further validated the Affimer technology and the company’s licensing business model, adding that the royalty licenses would “underpin the future high margin revenue from Affimer reagents”.

In a note to clients, analysts at City broker finnCap estimated that royalties would stand at around 10%, while also reiterating their 120p price target for the group.

Shares were up 2% at 25p.

--Adds share price and broker comment--

View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use